NCT04326348View on ClinicalTrials.gov

A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）

PHASE1UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 17, 2020

Primary Completion Date

January 31, 2022

Study Completion Date

July 31, 2022

Conditions
Hemophagocytic Lymphohistiocytosis
Interventions
DRUG

TQ05105

TQ05105 is a JAK2 inhibitor.

Trial Locations (1)

100050

RECRUITING

Beijing Friendship Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY